Candel Therapeutics (NASDAQ:CADL) Rating Increased to Buy at Bank of America

Candel Therapeutics (NASDAQ:CADL) Rating Increased to Buy at Bank of America

Bank of America upgraded Candel Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $12.00 to $18.00 in a report on Monday.

Candel Therapeutics (NASDAQ:CADL) Upgraded to “Buy” at Bank of America

Bank of America upgraded shares of Candel Therapeutics (NASDAQ:CADL – Free Report) from a neutral rating to a buy rating in a research report released on Monday morning, Marketbeat.com reports. Bank of America currently has $18.00 price target on the stock, up from their prior price target of $12.00. CADL has been the subject of […]